Neuraltus Pharmaceuticals Overview
- Year Founded
-
2004
- Status
-
Out of Business
- Employees
-
9
- Latest Deal Type
-
Out of Business
Neuraltus Pharmaceuticals General Information
Description
Developer of therapeutics designed to provide treatment of neurodegenerative diseases. The company's therapeutics are use to provide treatment of Lou Gehrig's disease and motor neurone disease, enabling healthcare providers to cure and understand the needs of people affected by this disease.
Contact Information
Website
www.neuraltus.comCorporate Office
- 1111 Bayhill Drive
- Suite 210
- San Bruno, CA 94066
- United States
Corporate Office
- 1111 Bayhill Drive
- Suite 210
- San Bruno, CA 94066
- United States
Neuraltus Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Out of Business | 01-Apr-2019 | Completed | Out of Business | |||
| 8. Later Stage VC | 01-Mar-2017 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series A3) | 24-May-2016 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 01-Jul-2015 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series A2) | 31-May-2012 | Completed | Generating Revenue | |||
| 4. Grant | 05-Nov-2010 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A1) | 26-Mar-2009 | Completed | Startup | |||
| 2. Early Stage VC (Series 3) | 24-Sep-2007 | $624K | $2.12M | Completed | Startup | |
| 1. Early Stage VC (Series 2) | 02-Mar-2006 | $1.5M | $1.5M | Completed | Startup |
Neuraltus Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series III-1 | ||||||||
| Series II-1 | ||||||||
| Series I-1 | ||||||||
| Series A3 | ||||||||
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series III | ||||||||
| Series II | 599,889 | $0.001000 | $0.2 | $2.5 | $2.5 | 1x | $0.72 | 0.3% |
| Series I | 500,000 | $0.001000 | $0.16 | $2.01 | $2.01 | 1x | $0.72 | 0.2% |
Neuraltus Pharmaceuticals Comparisons
Industry
Financing
Details
Neuraltus Pharmaceuticals Competitors (15)
One of Neuraltus Pharmaceuticals’s 15 competitors is Mitochon Pharmaceuticals, a Venture Capital-Backed company based in Blue Bell, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mitochon Pharmaceuticals | Venture Capital-Backed | Blue Bell, PA | ||||
| Semnur Pharmaceuticals | Formerly VC-backed | Palo Alto, CA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA |
Neuraltus Pharmaceuticals Patents
Neuraltus Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3370738-A2 | Treatment of neurodegenerative disease with sodium chlorite | Inactive | 02-Nov-2015 | ||
| US-20190060359-A1 | Treatment of neurodegenerative disease with sodium chlorite | Inactive | 02-Nov-2015 | ||
| WO-2017079161-A2 | Treatment of neurodegenerative disease with sodium chlorite | Inactive | 02-Nov-2015 | ||
| WO-2017079161-A3 | Treatment of neurodegenerative disease with sodium chlorite | Inactive | 02-Nov-2015 | ||
| AU-2015258892-A1 | Methods and compositions for treatment of macrophage-related disorders | Inactive | 16-May-2014 | A61K33/20 |
Neuraltus Pharmaceuticals Signals
Neuraltus Pharmaceuticals FAQs
-
When was Neuraltus Pharmaceuticals founded?
Neuraltus Pharmaceuticals was founded in 2004.
-
Where is Neuraltus Pharmaceuticals headquartered?
Neuraltus Pharmaceuticals is headquartered in San Bruno, CA.
-
What is the size of Neuraltus Pharmaceuticals?
Neuraltus Pharmaceuticals has 9 total employees.
-
What industry is Neuraltus Pharmaceuticals in?
Neuraltus Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Neuraltus Pharmaceuticals a private or public company?
Neuraltus Pharmaceuticals is a Private company.
-
What is Neuraltus Pharmaceuticals’s current revenue?
The current revenue for Neuraltus Pharmaceuticals is .
-
How much funding has Neuraltus Pharmaceuticals raised over time?
Neuraltus Pharmaceuticals has raised $47.8M.
-
Who are Neuraltus Pharmaceuticals’s competitors?
Mitochon Pharmaceuticals, Semnur Pharmaceuticals, NeuroNascent, Genentech, and Neurona Therapeutics are some of the 15 competitors of Neuraltus Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process